{"disease":{"id":"osteolytic-bone-metastases-of-breast-cancer","name":"Osteolytic Bone Metastases of Breast Cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pamidronate","indication_name":"Osteolytic Bone Metastases of Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pamidronate","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Hypoxanthine-guanine phosphoribosyltransferase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pamidronic-acid","indication_name":"Osteolytic Bone Metastases of Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aredia","generic_name":"PAMIDRONIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Bisphosphonate","quality_score":36,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}